Tagged Articles

acute kidney injury 71 articles

Acknowledgement of PPI risks is decades late, researchers say

In a letter published in Gut, Norwegian researchers comment on two recent studies linking the use of acid-reducing proton pump inhibitors, or PPIs, to gastric cancer. Hong Kong researchers published findings in early November that long-term PPIs use, even after Helicobacter pylori eradication therapy, is still associated with an increased risk of gastric cancer. At the same time a Swedish study reported incidence of gastric cancer to be linked to long-term PPI use. In their letter titled, “Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man,” Professor Helge Lyder Waldum, Department of Clinical ... Read More

PPI Kidney Injury cases centralized into MDL in New Jersey

On July 27, the Judicial Panel on Multidistrict Litigation (JPML) heard arguments on a motion to centralize 172 claims against proton pump inhibitors (PPIs) in a multidistrict litigation (MDL). The Panel granted the motion to centralize and will establish the MDL in the U.S. District for New Jersey where the most PPI claims are currently pending. Judge Claire C. Cecchi will preside over the MDL. It was plaintiffs’ second request to see these similar claims alleging kidney damage after using the popular acid-reducing drugs consolidated. The Panel had previously denied a similar motion requesting consolidation of PPI cases earlier this ... Read More

Farxiga lawsuits consolidated by Judicial Panel on Multidistrict Litigation

The U.S. Judiciary Panel on Multidistrict Litigation (JPML) created a new product liability MDL involving over kidney-related injuries with the type 2 diabetes drug Farxiga. The 18 actions consolidated in New York are currently pending in six federal district courts and share common questions of fact that would benefit from a centralized pre-trial MDL docket, the JPML concluded. The lawsuits, waged at the makers of Farxiga, as well as its so-called sister drug Xigduo XR, Bristol-Myers Squibb Co. and AstraZeneca, allege that use of the diabetes medications can cause acute kidney injury and diabetic ketoacidosis, a serious condition in which ... Read More

Class of type 2 diabetes drug may offer heart benefits, but patients must weigh other risks

Data presented at the American College of Cardiology Scientific Session suggested that patients taking a class of type 2 diabetes drugs called SGLT2 inhibitors were at lower risk of being hospitalized for heart failure. But that benefit may come at a cost. People with type 2 diabetes are already at risk for various cardiovascular complications. Heart failure is one of the most common, said Mikhail Kosiborod, MD, professor of medicine at the University of Missouri School of Medicine in Kansas City in an interview with Cardiology Today. “Not only that, but it’s arguably the most morbid of (heart related) complications ... Read More

New SGLT2 inhibitors in development despite serious side effects

Since the new class of type 2 diabetes drugs known as SGLT2 inhibitors hit the market in 2013, the drugs have been repeatedly called out by the Food and Drug Administration (FDA) for various but serious adverse events. Yet, drug makers continue to develop new versions of this drug hoping to cash in on the billions of dollars spent on diabetes treatments. SGLT2 inhibitors currently on the market include Invokana and Invokamet, Farxiga and Jardiance. The drugs work to lower blood sugar by causing the kidneys to remove sugar from the body through the urine. Drug makers Merck and Pfizer ... Read More

Invokana heart benefits may not outweigh other risks for patients with diabetes

A newer class of type 2 diabetes drugs called SGLT2 inhibitors are being credited in recent studies for reducing the risk of hospitalization due to heart failure in diabetic patients, but the news doesn’t overshadow the drug’s laundry list of risks. Patients considering treatment with an SGLT2 inhibitors, such as Invokana and Invokamet, should first consider the potentially life threatening side effects. Invokana was the first SGLT2 inhibitor to hit the market in March 2013. Shortly thereafter, the Food and Drug Administration (FDA) issued a warning that the drugs had been linked to reports of ketoacidosis, a serious condition in ... Read More

Global warming may lead to more cases of type 2 diabetes

There’s another reason to fear global warming. Not only does a mere 1 degree Celsius increase on average raise sea levels, lower crop yields and shrink habitats for vulnerable species, a new study suggests that an additional 100,000 people could develop diabetes as a result of climate change. Climate control experts previously warned that such changes in the world’s temperatures could lead to the spread of conditions like as mosquito-born malaria and dengue fever. It could also lead to the spread of water-borne illnesses like cholera. Diabetes is a breed of its own. The chronic condition isn’t contagious, but those ... Read More

National Kidney Month: Some medications linked to acute kidney injury

March is National Kidney Month is an awareness campaign that should be important to people with type 2 diabetes. That is because diabetes is the leading cause of kidney failure, the last stage of kidney disease in which the kidneys fail to filter impurities from the blood, requiring kidney transplantation or dialysis. Many conditions, diseases and medicines can create situations that lead to acute and chronic kidney disease that can lead to kidney failure. Chronic kidney disease (CKD) is usually caused by a long-term disease like diabetes or high blood pressure that slowly damages the kidneys and reduces function over ... Read More

Will the FDA add new amputation warning to popular diabetes drugs?

Last month, the European Medicines Agency (EMA) announced it was adding warnings to the safety labels of a popular class of type 2 diabetes drugs to caution about an increased risk for lower limb amputations, particularly of the foot and toe. U.S. drug regulators have yet to issue similar warnings. The label update stems from a review of data from two ongoing clinical trials involving type 2 diabetes drugs containing canagliflozin, which are known in the U.S. by the brand names Invokana and Invokamet. The data showed that patients who used these medications were more likely to undergo lower limb amputation ... Read More

Merck, Pfizer seek FDA approval for new diabetes treatment

The Food and Drug Administration (FDA) has accepted three New Drug Applications (NDAs) from Merck and Pfizer Inc., for drugs containing ertugliflozin, a new medication from a class of diabetes drugs known as SGLT2 inhibitors. The three NDAs include an ertugliflozin only treatment, a fixed-dose combination of ertugliflozin and the diabetes drug Januvia (sitagliptin), and a fixed-dose combination of ertugliflozin and the first-line diabetes drug metformin. The FDA is expected to review the medication in December 2017. Additionally, the European Medicines Agency (EMA) has also agreed to review three drug applications containing ertugliflozin. The applications are supported by studies comprised ... Read More